— Know what they know.
Not Investment Advice

CATX AMEX

Perspective Therapeutics, Inc.
1W: -45.7% 1M: -52.8% 3M: -58.5% YTD: -57.4% 1Y: -58.7% 3Y: -57.8% 5Y: -80.7%
$1.19
-0.02 (-1.65%)
After Hours: $1.20 (+0.01, +0.84%)
Weekly Expected Move ±18.3%
$1 $1 $2 $2 $2
AMEX · Healthcare · Medical - Devices · Tech Score Strong Sell · Power 30 · $135.8M mcap · 71M float · 2.74% daily turnover · Short 59% of daily vol
Credit Risk of going bust: higher than 66% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.4%), Perspective Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.0M against a stock market value of $138.1M.
Distance to default 3.75 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.9M (short-term plus half of long-term), stock volatility 103.0%; Altman Z -0.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$135.8M
52W Range1.06-6.16
Volume8,735,586
Avg Volume1,942,768
Beta1.85
Dividend—
Analyst Ratings
9 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOJohan Spoor
Employees165
SectorHealthcare
IndustryMedical - Devices
IPO Date2005-11-10
2401 Elliott Avenue
Seattle, WA 98121
US
509 375 1202
About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Recent Insider Trades

NameTypeSharesPriceDate
Lantheus Alpha Thera S-Sale 167,149 $3.15 2026-09-04
Lantheus Alpha Thera S-Sale 80,783 $3.11 2026-09-03
Lantheus Alpha Thera S-Sale 42,129 $3.11 2026-09-02
Lantheus Alpha Thera S-Sale 35,769 $3.12 2026-09-01
Lantheus Holdings, I S-Sale 35,769 $3.12 2026-09-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms